Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine

Pediatric Hematology and Oncology

Volumn 22, Issue 5, 2005, Pages 441-445

  Sastry, Jairam ^a   Kellie, Stewart J ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Amifostine; Cisplatin; Nephrotoxicity; Neurotoxicity

Indexed keywords

AMIFOSTINE; CISPLATIN; ETOPOSIDE; PENTETATE TECHNETIUM TC 99M;

ADOLESCENT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG INDICATION; DRUG MEGADOSE; FEMALE; FOOD AND DRUG ADMINISTRATION; GERM CELL TUMOR; HUMAN; KIDNEY FAILURE; NEPHROTOXICITY; NEUROBLASTOMA; NEUROTOXICITY; OTOTOXICITY; OVARY CARCINOMA; SMALL CELL CARCINOMA; TREATMENT OUTCOME;

ADOLESCENT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FATAL OUTCOME; FEMALE; HEARING; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; NERVOUS SYSTEM; OVARIAN NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 22244478065     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590964381     Document Type: Article

References (16)

1. Hartmann O, Pinkerton CR, Philip T, et al. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988;6:44-50.
2. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994;12:2607-2613.
3. Tada T, Takizawa T, Nakazato F, et al. Treatment of intracranial non-germinomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue. J Neuro-Oncol. 1999;44:71-76.
4. Glover DJ, Glick JH, Weiler C, et al. WR-2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574-578.
5. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer. 1988;61:2192-2195.
6. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2102-2112.
7. Rubin JS, Wadler S, Beitler JJ, et al. Audiological findings in a phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol. 1995;109;744-777.
8. Ramnath N, LoRusso P, Simon M, et al. Phase II evaluation of cisplatin and WR-2721 for refractory metastatic breast cancer. Am J Clin Oncol 1997;20:368-372.
9. Rick O, Beyer J, Schwella N, et al. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol. 2001;12:1151-1155.
10. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anti-Cancer Drugs. 2002;13:181-209.
11. Cavaletti G, Cascinu S, Venturino P, et al. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res. 1996;16:3149-3159.
12. Green D, Bensley D, Schein P. Preclinical evaluation of WR 1513127: an orally active chemotherapy protector. Cancer Res. 1994;54:738-741.
13. Budd GT, Lorenzi V, Ganapathi R, et al. Amifostine potential for clinically useful cytoprotection. Support Care Cancer. 1994;2:380-384.
14. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 2001;92:914-923.
15. Souid AK, Fahey RC, Dubowy RL, et al. Determination of the cytoprotective agent WR-2721 (amifostine, ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Cancer Chemother Pharmacol. 1998;42:400-406.
16. Souid AK, Fahey RC, Dubowy RL, et al. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. Cancer Chemother Pharmacol. 1999;44:498-504.